Nasdaq · Biotech stocks database
AMGN (Amgen Inc.) stock: $385.65, $208.49B market cap, $13.99B cash, $246.36B EV, $220.93B fully diluted market cap. Next expected readout: Sep-26. Lead program: Dazodalibep (Sjögren's Syndrome (SS)), Phase 3. Data from Fully Diluted's biotech stocks database.
| Cash | $13,989.0M |
|---|---|
| Debt | $51,859.0M |
| Net cash | -$37,870.0M |
| Enterprise value | $246,364.7M |
| Basic shares | 540.6M shares |
| Fully diluted shares | 572.9M shares |
| Fully diluted market cap | $220,926.9M |
| Cash per share | $25.88 |
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Loading AMGN daily closes…
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Oct 7 - Nov 18 | Maridebart Cafraglutide | Phase 1 | Overweight; Obesity | — |
| Oct 15 - Nov 26 | Evolocumab Drug Substance A (Test) | Phase 1 | Healthy Participants | — |
| Nov 5 - Dec 17 | AMG 513 | Phase 1 | Cardiometabolic Disease | — |
| Dec 3, 2026 - Jan 14, 2027 | Dazodalibep | Phase 3 | Sjögren's Syndrome (SS) | H2 2026 |
| Dec 12, 2026 - Jan 23, 2027 | anvumetostat | Phase 2 | MTAP-deleted NSCLC | — |
| Dec 12, 2026 - Jan 23, 2027 | Anvumetostat | Phase 1 | Thoracic Tumors; Non-small Cell Lung Cancer | — |
| Dec 12, 2026 - Jan 23, 2027 | Anvumetostat | Phase 1 | Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers | — |
| Dec 27, 2026 - Feb 7, 2027 | Maridebart cafraglutide | Phase 1 | Type 2 Diabetes Mellitus | — |
| Dec 30, 2026 - Feb 10, 2027 | COC | Phase 1 | Overweight; Obesity | — |
| Jan 11 - Feb 22 | Anvumetostat | Phase 2 | Advanced MTAP-null Solid Tumors | — |
| Jan 25 - Mar 8 | ABP 234 | Phase 3 | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | — |
| Jan 28 - Mar 11 | Sotorasib | Phase 1 | Advanced Solid Tumors; Kirsten Rat Sarcoma (KRAS) pG12C Mutation | — |
| Feb 11 - Mar 25 | Tarlatamab | Phase 1 | Small Cell Lung Carcinoma | — |
| Feb 17 - Mar 31 | AMG 732 | Phase 2 | Thyroid Eye Disease | — |
| Feb 25 - Apr 8 | Romosozumab | Phase 1 | Healthy Participants | — |
| Mar 4 - Apr 15 | Maridebart Cafraglutide | Phase 3 | Obesity | — |
| Mar 4 - Apr 15 | Maridebart cafraglutide | Phase 3 | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | — |
| Mar 31 - May 12 | Xaluritamig | Phase 1 | Prostate Cancer | — |
| Apr 24 - Jun 5 | Xaluritamig | Phase 1 | Prostate Cancer; High-risk Biochemical Recurrence; High Risk Biochemical Recurrence of Non-metastatic Castration-sensitiv | — |
| May 12 - Jun 23 | AMG 691 | Phase 1 | Healthy Participants | — |
| May 22 - Jul 3 | AMG 691 | Phase 1 | Asthma | — |
| May 25 - Jul 6 | Inebilizumab | Phase 2 | Neuromyelitis Optica Spectrum Disorder | — |
| May 31 - Jul 12 | Ocrelizumab (US) | Phase 3 | Relapsing-remitting Multiple Sclerosis (RRMS) | — |
| Jun 5 - Jul 17 | Tarlatamab | Phase 1 | Extensive Stage Small Cell Lung Cancer | — |
| Jun 8 - Jul 20 | Maridebart cafraglutide | Phase 3 | Obesity Disease | — |
| Jun 12 - Jul 24 | Daratumumab | Phase 2 | Multiple Myeloma; Refractory Multiple Myeloma; Multiple Myeloma in Relapse | — |
| Jun 15 - Jul 27 | Romosozumab | Phase 3 | Osteogenesis Imperfecta | — |
| Jun 29 - Aug 10 | Tarlatamab | Phase 2 | Metastatic/Locally Advanced Small-Cell Lung Cancer; Metastatic/Locally Advanced Poorly Differentiated NEC | — |
| Aug 11 - Sep 22 | Etelcalcetide | Phase 3 | Secondary Hyperparathyroidism | — |
| Aug 11 - Sep 22 | Sotorasib | Phase 3 | Non-Small Cell Lung Cancer (NSCLC) | — |
| Aug 16 - Sep 27 | Tarlatamab | Phase 3 | Extensive-Stage Small-Cell Lung Cancer; Small-Cell Lung Cancer | — |
| Aug 29 - Oct 10 | Avacopan | Phase 3 | Vasculitis | — |
| Sep 11 - Oct 23 | ABP 938 8 mg | Phase 3 | Neovascular Age-related Macular Degeneration; nAMD | — |
| Oct 13 - Nov 24 | bemarituzumab, paclitaxel, ramucirumab | Phase 2 | Metastatic Gastro-esophageal Adenocarcinoma | — |
| Nov 5 - Dec 17 | Tarlatamab | Phase 3 | Small Cell Lung Cancer | — |
| Nov 10 - Dec 22 | Maridebart cafraglutide | Phase 3 | Obesity; Obstructive Sleep Apnea | — |
| Nov 10 - Dec 22 | Maridebart cafraglutide | Phase 3 | Obstructive Sleep Apnea | — |
| Nov 10 - Dec 22 | Maridebart cafraglutide | Phase 2 | Overweight or Obesity and Elevated Liver Fat | — |
| Nov 13 - Dec 25 | AMG 127 | Phase 1 | Diabetes Mellitus, Type 2 | — |
| Jan 5 - Feb 16 | Blinatumomab | Phase 2 | B Cell Precursor Acute Lymphoblastic Leukemia | — |
| Feb 6 - Mar 19 | Maridebart Cafraglutide | Phase 3 | Obesity; Overweight; Diabetes Mellitus, Type 2 | — |
| Feb 6 - Mar 19 | Maridebart cafraglutide | Phase 3 | Obesity; Overweight | — |
| Feb 10 - Mar 23 | Tarlatamab | Phase 2 | Relapsed/Refractory Small Cell Lung Cancer | — |
| Feb 14 - Mar 27 | Maridebart Cafraglutide | Phase 3 | Obesity or Overweight | — |
| Feb 21 - Apr 3 | ABP 234 | Phase 3 | Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | — |
| Mar 7 - Apr 18 | ABP 206 | Phase 3 | Melanoma | — |
| Mar 11 - Apr 22 | AMG 732 | Phase 2 | Thyroid Eye Disease | — |
| Apr 29 - Jun 10 | Tarlatamab | Phase 1 | Extensive Stage Small Cell Lung Cancer | — |
| May 2 - Jun 13 | Apremilast | Phase 3 | Active Juvenile Psoriatic Arthritis | — |
| May 8 - Jun 19 | Xaluritamig | Phase 1 | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | — |
| May 12 - Jun 23 | Olpasiran | Phase 3 | Atherosclerotic Cardiovascular Disease | — |
| May 30 - Jul 11 | AMG 410 | Phase 1 | KRAS Altered Advanced or Metastatic Solid Tumors | — |
| Jul 2 - Aug 13 | ZL-1310 | Phase 1 | Small Cell Lung Cancer | — |
| Jul 12 - Aug 23 | Tezepelumab | Phase 3 | Asthma | — |
| Jul 27 - Sep 7 | Olpasiran | Phase 3 | Cardiovascular Disease | — |
| Jul 30 - Sep 10 | Pegloticase | Phase 3 | Uncontrolled Gout | — |
| Aug 11 - Sep 22 | Maridebart Cafraglutide | Phase 3 | Atherosclerotic Cardiovascular Disease; Overweight; Obesity | — |
| Aug 11 - Sep 22 | Maridebart cafraglutide | Phase 3 | Heart Failure With Preserved Ejection Fraction; Heart Failure With Mildly Reduced Ejection Fraction; Obesity | — |
| Aug 12 - Sep 23 | Sotorasib | Phase 2 | Advanced Solid Tumors | — |
| Sep 8 - Oct 20 | AMG 436 | Phase 1 | Metastatic or Locally Advanced Solid Tumors With Microsatellite Instab | — |
| Sep 17 - Oct 29 | Inebilizumab | Phase 2 | Systemic Lupus Erythematosus; Active Refractory Rheumatoid Arthritis | — |
| Nov 6 - Dec 18 | FOLFIRI Regimen | Phase 3 | Metastatic Colorectal Cancer | — |
| Jan 12 - Feb 23 | Tarlatamab | Phase 2 | Advanced Neuroendocrine Carcinomas of The Digestive System; Advanced Neuroendocrine Carcinomas Unknown Primary Origin | — |
| Jan 16 - Feb 27 | Blinatumomab | Phase 2 | Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia; Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia | — |
| Feb 13 - Mar 27 | Xaluritamig | Phase 3 | Metastatic Castration-resistant Prostate Cancer | — |
| Feb 15 - Mar 29 | Tarlatamab | Phase 3 | Small-cell Lung Cancer; Extensive Stage Small-cell Lung Cancer | — |
| Mar 14 - Apr 25 | Etelcalcetide | Phase 3 | Secondary Hyperparathyroidism; Chronic Kidney Disease | — |
| Apr 24 - Jun 5 | Tezepelumab | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | — |
| Apr 24 - Jun 5 | Tezepelumab | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | — |
| Jun 21 - Aug 2 | Tarlatamab | Phase 2 | Small Cell Lung Cancer (SCLC) | — |
| Oct 19 - Nov 30 | Blinatumomab | Phase 3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymp | — |
| Oct 26 - Dec 7 | Romiplostim | Phase 3 | Primary Immune Thrombocytopenia | — |
| Dec 12, 2029 - Jan 23, 2030 | Interferon gamma-1b | Phase 2 | Acute Myeloid Leukemia; Myelodysplastic Syndromes | — |
| Jan 22 - Mar 5 | Dazodalibep | Phase 3 | Sjögren's Syndrome | H2 2026 |
| Feb 18 - Apr 1 | Xaluritamig | Phase 3 | Metastatic Castration-resistant Prostate Cancer | — |
| Mar 21 - May 2 | Apremilast | Phase 3 | Behçet Disease | — |
| Apr 24 - Jun 5 | Inebilizumab | Phase 2 | Generalized Myasthenia Gravis | — |
| May 3 - Jun 14 | AMG 509 | Phase 1 | Prostate Cancer | — |
| Jun 1 - Jul 13 | Tarlatamab | Phase 3 | Limited Stage Small Cell Lung Cancer; Small Cell Lung Cancer | — |
| Jul 7 - Aug 18 | Xaluritamig | Phase 1 | Ewing Sarcoma | — |
| Jul 11 - Aug 22 | Tarlatamab | Phase 1 | Extensive Stage Small Cell Lung Cancer | — |
| Aug 12 - Sep 23 | Avacopan | Phase 3 | Granulomatosis With Polyangiitis; Wegener's; GPA | — |
| Sep 10 - Oct 22 | Xaluritamig | Phase 1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | — |
| Jul 22 - Sep 2 | Inebilizumab | Phase 2 | Immunoglobulin G4-related Disease | — |
| Aug 4 - Sep 15 | YL201 | Phase 1 | Small Cell Lung Cancer | — |
| Sep 10 - Oct 22 | Inebilizumab | Phase 3 | Autoimmune Hepatitis; AIH | — |
| Dec 1, 2031 - Jan 12, 2032 | Olpasiran | Phase 3 | Cardiovascular Disease | — |
| Feb 10 - Mar 23 | Blinatumomab | Phase 3 | Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic | — |
| Apr 28 - Jun 9 | Apremilast | Phase 3 | Behçet's Disease; Juvenile Psoriatic Arthritis | — |
| Dec 13, 2037 - Jan 24, 2038 | Tarlatamab | Phase 3 | Limited Stage Small-Cell Lung Cancer | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.